Talk:Tyrosine kinase inhibitor
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Mechanisms edit
Courtesy notice (article was last updated on 8 Sept 2020.) Mechanisms section states that TKIs may be used to treat non-cancer inflammatory conditions, but "Until now TKIs have not been developed for the treatment of such conditions." However, in October 2014, the FDA approved nintedanib (Ofev) for treatment of idiopathic pulmonary fibrosis. See https://emedicine.medscape.com/article/301226-medication . At least one Canadian jurisdiction has also approved the conditional use of nintedamib to treat IPF related to rheumatoid arthritis and its treatment. See 2020 Nova Scotia Formulary, Appendix II (PDF p 355), c/o https://novascotia.ca/dhw/pharmacare/formulary.asp
Sorry I don't have time for additional research on this topic, but the article author may want to re-update. Cliffewiki (talk) 17:12, 22 April 2021 (UTC)
- Thanks a lot for pointing this out! --ἀνυπόδητος (talk) 18:50, 22 April 2021 (UTC)